Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHED-CM in ALS
NCT06889857Phase 1Active, not recruiting
- Sponsor
- Hitonowa Medical
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Mesenchymal Stem Cells, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHED-CM in amyotrophic lateral sclerosis (ALS), sponsored by Hitonowa Medical. Primary endpoints: All Adverse Events, Number of Clinically Significant Changes in Laboratory Test Results at Week 16 and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
SHED-CM
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06889857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889857.